CJC-1295 (no DAC)

Also known as: Mod GRF 1-29, Modified GRF (1-29)

**Mechanism of Action** CJC-1295 (without DAC) is a synthetic tetrasubstituted analog of growth hormone-releasing hormone (GHRH) comprising amino acids 1–29. Its structural modifications (e.g., substitution at positions 2, 8, 15, and 27) confer resistance to dipeptidyl peptidase IV (DPP-IV) degradation, extending its half-life relative to endogenous GHRH. The peptide binds to pituitary GHRH receptors, stimulating pulsatile growth hormone (GH) secretion in a manner that preserves the natural ultradian rhythm. Unlike the DAC-conjugated variant, this form lacks a drug affinity complex, resulting in a shorter duration of action and a more transient GH pulse. **Key Research Findings** Preclinical and early-phase studies demonstrate that CJC-1295 (no DAC) dose-dependently elevates GH and insulin-like growth factor 1 (IGF-1) levels without abolishing endogenous GH pulsatility. In rodent models, repeated administration increased lean body mass and bone density, with minimal desensitization of the somatotropic axis. Human trials (Phase I/II) reported transient increases in GH and IGF-1 over 2–4 hours post-injection, with mild side effects including flushing and injection-site reactions. No significant alterations in glucose homeostasis or cortisol were observed in short-term studies. However, long-term safety data remain absent. **Clinical Relevance** CJC-1295 (no DAC) is classified as an experimental peptide with no approved therapeutic indications. Its potential applications—such as treating GH deficiency, sarcopenia, or frailty—are speculative and require rigorous clinical validation. Due to its GH-releasing properties, it is subject to regulatory restrictions in many jurisdictions. **For research purposes only — not medical advice.**

Key data

Research & studies

Frequently asked questions

Related peptides